Polydopamine-Based Nanocarriers for Photosensitizer Delivery.

Area of Science:

• Biomaterials Science
• Nanotechnology
• Cancer Therapy

Background:

• Photodynamic therapy (PDT) is a non-invasive cancer treatment relying on photosensitizers (PS).
• Free PSs suffer from poor stability, rapid clearance, and low solubility, limiting their clinical efficacy.
• Nanocarriers offer a strategy to improve PS delivery and therapeutic outcomes.

Purpose of the Study:

• To review recent advancements in polydopamine (PDA) nanocarriers for PS delivery in PDT.
• To introduce and analyze three distinct strategies for integrating PSs with PDA nanocarriers.
• To discuss the challenges and future prospects of PDA-based PS nanocarriers.

Main Methods:

• Literature review of recent developments in PDA nanocarriers for PS delivery.
• Categorization and analysis of three primary strategies for PS-PDA conjugation.
• Discussion of advantages, disadvantages, challenges, and opportunities.

Main Results:

• PDA nanocarriers demonstrate favorable biocompatibility, ease of preparation, and versatile functionality.
• Various strategies exist for combining PSs with PDA, each with unique benefits and drawbacks.
• PDA-based nanocarriers effectively address the limitations of free PSs.

Conclusions:

• PDA nanocarriers represent a significant advancement in PS delivery for PDT.
• Further research into optimized strategies and clinical translation is warranted.
• PDA-based nanocarriers hold great potential for improving cancer therapy outcomes.